Benitec Biopharma $BNTC entered in an oncology-focused R&D agreement with Nantworks under which the former will lead preclinical evaluation and clinical development of certain assets based on its ddRNAi technology. Specifically, it will lead clinical development of a Phase 2 gene-silencing asset for the treatment of a solid tumor indication and the commencement of a ddRNAi program to develop a second-generation therapeutic for the indication. A formal agreement is expected by the year-end.